OneRobotics (Shenzhen) Co., Ltd. 臥安機器人（深圳）股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 股份代號： 6600 全球發售 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 （按英文字母順序） （深圳）股份有限公司 OneRobotics (Shenzhen) Co., Ltd. 臥安機器人（深圳）股份有限公司 重 要 提 示 閣下如對本招股章程任何內容有任何疑問，應諮詢獨立專業意見。 OneRobotics (Shenzhen) Co., Ltd. 臥安機器人 OneRobotics (Shenzhen) Co., Ltd. 臥 安 機 器 人（ 深 圳 ）股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售項下的發售股份數目 | ： | 22,222,300股H股（視乎超額配股權行使與否 | | --- | --- | --- | | | | 而定） | | 香港發售股份數目 | ： | 2,222,300股H股（可予重新分配） | | 國際發售股份數目 | ： | 20,000,000股H股（可 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司（「香 港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示不會就 因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 除非本公告另有界定，否則本公告所用詞彙與臥安機器人（深圳）股份有限公司（「本公司」）發佈的 日期為2025年12月18日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅作參考用途，並不構成收購、購買或認購證券的邀請或要約。潛在投資者應先行閱讀招股 章程有關下文所述本公司及全球發售的詳細資料，方決定是否投資於發售股份。本公司並無亦不 會根據1940年美國《投資公司法》（經修訂）進行登記。有關發售股份的任何投資決定應僅依賴招股 章程所提供的資料而作出。 本公告不會直接或間接於美國或向美國（包括其領土及屬地、美國任何州及哥倫比亞特區）或向任 何人士（定義見《1933年美國證券法》（經不時修訂）（「美國證券法」）S規例）或於法律禁止進行有關派 發的任何其他司法權區發佈、刊發或派發。本公告並不構成或組成在美國或任何其他司法權區的 任何要約出售或招攬購買或 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Post Hearing Information Pack, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Post Hearing Information Pack. Post Hearing Information Pack of OneRobotics (Shenzhen) Co., Ltd. 臥 安 機 器 人（ 深 圳 ）股 份 有 限 公 司 (the ''Company'') ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性 或完整性亦不發表任何意見，並明確表示概不就因本聆訊後資料集全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 OneRobotics (Shenzhen) Co., Ltd. 臥 安 機 器 人（ 深 圳 ）股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 聆訊後資料集 警告 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作提供資訊予香港公眾人士。 本聆訊後資料集為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長註冊的本 公司招股章程作出投資決定，該文件的副本將於發售期內向公眾人士提供。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文件 中的資料作出任何投資決定 ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完 整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 OneRobotics (Shenzhen) Co., Ltd. 臥 安 機 器 人（ 深 圳 ）股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」）的要 求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長註冊的本 公司招股章程作出投資決定，該文件的副本將於發售期內向公眾人士提供。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據本文件 中的資料作出任何投資決定； (b) 在聯交 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of OneRobotics (Shenzhen) Co., Ltd. 臥 安 機 器 人（ 深 圳 ）股 份 有 限 公 司 (the ''Company'') (A joint stock company incorporated ...

–1– (a) the publication of this announcement on the Stock Exchange's website does not give rise to any obligation of the Company, its joint sponsors, sponsor-overall coordinators, advisers or members of the underwriting syndicate to proceed with an offering or a placing in Hong Kong or any other jurisdiction. There is no assurance that the Company will proceed with the offering or the placing; (b) the application to which this announcement relates has not been approved for listing and the Stock Exchange and ...

（「本公司」） （於中華人民共和國註冊成立的股份有限公司） 警告 本公告乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會 （「證監會」）的要求而刊發，僅用作提供資料予香港公眾人士。 閣下閱覽本公告，即表示 閣下知悉、接納並向本公司、其聯席保薦人、保薦人兼 整體協調人、顧問或包銷團成員表示同意： – 1 – (a) 於聯交所網站登載本公告，並不引起本公司、其聯席保薦人、保薦人兼整體協 調人、顧問或包銷團成員須在香港或任何其他司法權區進行發售或配售的任何 責任。本公司最終會否進行發售或配售仍屬未知之數； (b) 本公告所涉及的上市申請並未獲批准，聯交所及證監會或會接納、發回或拒絕 有關的公開發售及╱或上市申請； (c) 本公告不應被視為誘使認購或購買任何證券，亦無意構成該等勸誘； (d) 本公司或其任何聯屬公司、其顧問或包銷團成員概無於任何司法權區透過刊發 本公告而發售任何證券或招攬認購或購買任何證券的要約； (e) 本公告（及其所載資料）僅供參考，並不構成或組成於美國（包括其領土及屬地、 美國任何州以及哥倫比亞特區）或提呈發行或出售或招攬購買、認購或以其他 方式收購本公司任何證券的任何要約即 ...

Product Development and Innovation - SciClone's core product, Zadaxin, capitalized on market opportunities in 2023, benefiting a wide range of patients[26]. - The in-licensed product, Danyelza, officially launched in China, further expanding SciClone's product portfolio[26]. - SciClone obtained the exclusive license to develop and commercialize the innovative product Orserdu in China[26]. - The Phase III clinical trial of the new antimicrobial product Vaborem completed patient enrollment, indicating positive progress in the pipeline[26]. - The company is committed to identifying innovative products with first-in-class or best-in-class potential to boost future performance growth momentum[27]. - The company plans to increase investment in research and development and expand its product pipeline to launch more differentiated and high-quality innovative drugs[31]. - The company has over 10 ongoing clinical studies in China and overseas, focusing on oncology, severe infections, and vaccines[52]. - The company is actively seeking to develop products focusing on targeted therapies, immunotherapy, and enhanced chemotherapy options[62]. - Tα1 is being evaluated in multiple clinical studies, including its efficacy and safety in advanced gastric cancer and LA-NSCLC[54]. - The company has a portfolio of 10 pipeline drug candidates, with 6 in phase III or later stages overseas and a fast-to-market strategy in China[62]. - The company is conducting a US Phase II trial for PT-112, a platinum-containing compound for late-stage prostate cancer, with a Phase 2a trial already completed[71]. - Vaborem, a carbapenem and β-lactamase inhibitor, obtained IND approval in March 2023, with the first subject dosed in July 2023, and subject enrollment completion expected in January 2024[67]. - Danyelza, targeting high-risk neuroblastoma, was officially commercialized in July 2023, with BLA approval obtained in Macau in June 2023 and submission in Hong Kong in January 2023[70]. - Tα1 has been included in three additional treatment guidelines and a nationwide patient education manual for liver cancer as of December 31, 2023[55]. - The company is focusing on expanding its pipeline with innovative therapies targeting solid tumors and specific cancer mutations[71]. Financial Performance - For the year ended December 31, 2023, the company's revenue reached RMB3,155.6 million, an increase of 14.8% compared to the previous year[31]. - Gross profit for 2023 was RMB2,356.2 million, reflecting a growth of 13.8% from 2022[34]. - Net profit increased by 31.2% to RMB1,121.9 million compared to the net profit for the year ended December 31, 2022[34]. - Core net profit, excluding one-off changes, was approximately RMB1,236.9 million, up by about 19.5% year-over-year[34]. - Operating cash flow achieved RMB1,404.3 million, representing an increase of RMB220.7 million or 18.6% from the previous year[34]. - Selling and marketing expenses increased by 13.5%, while research and development expenses grew by 37.8% compared to the last year[39]. - The total cash and cash equivalents amounted to approximately RMB2.2 billion as of December 31, 2023[38]. - The company reported a profit for the year attributable to the owner of RMB 1,121.9 million, a 31.1% increase from RMB 855.4 million in 2022[95]. - The company's profit for the year rose by 31.2% to RMB1,121.9 million in 2023, up from RMB855.4 million in the previous year[118][123]. - Other net losses decreased by RMB103.3 million, or 66.5%, to RMB52.1 million in 2023, primarily due to the absence of one-off costs recorded in 2022[116][119]. Strategic Initiatives and Market Expansion - The company is proactively implementing strategic transformation and increasing investments to improve its revenue mix and enhance R&D capabilities[27]. - The company aims to achieve better operational efficiency and compliance through investments in digital technologies and the GTP model[47]. - The company collaborates with various DTP chains and commercial insurance providers to expand its market reach[48]. - Continuous growth of marketed products is driven by clinical research and academic promotion efforts[51]. - The company aims to leverage its expertise in sales, marketing, and regulatory affairs to distribute Orserdu in China post-approval[74]. - The company is exploring pilot launch opportunities in Bo'ao of Hainan and the Greater Bay Area[79]. - The company aims to enhance cooperation with partners, including Pfizer and Baxter, to expand its market presence[94]. Corporate Governance and Leadership - The company has a strong leadership team with diverse backgrounds in pharmaceuticals, finance, and management, enhancing its strategic direction[146]. - The company is focused on expanding its market presence and leveraging the expertise of its board members for strategic growth[148]. - The board's composition reflects a commitment to governance and strategic oversight, with members holding key positions in various industry organizations[148]. - The company emphasizes the importance of corporate governance in formulating business strategies and policies, enhancing transparency and accountability[187]. - The Board confirmed compliance with the Model Code throughout the year ended December 31, 2023, ensuring ethical conduct in securities transactions[188]. - The Board consists of ten directors, including two executive directors, four non-executive directors, and four independent non-executive directors[192]. - The Board maintains a balance of skills, experience, and diversity appropriate to the company's business requirements[190]. - The company has established written guidelines for securities transactions by employees likely to possess unpublished price-sensitive information[190]. - The Board has consistently met the Listing Rules requirements for the appointment of at least three Independent Non-executive Directors, representing more than one-third of the Board[195]. Market Trends and Challenges - The company anticipates potential fluctuations in short-term performance, which may differ from investor expectations[27]. - The company continues to focus on maintaining steady development in a complex and volatile business environment[25]. - The increased demand for Zadaxin was driven by the prevalence of infectious diseases and the public's understanding of immune modulation benefits post-COVID-19[100]. - The incidence of carbapenem-resistant Klebsiella pneumonia (CR-KP) infections is rising rapidly in China over the last 10 years[82]. - Vaborem is specifically developed to inhibit carbapenem-resistant enterobacterales (CRE), addressing significant unmet medical needs in China[83].

智通财经APP讯，赛生药业(06600)及要约人Silver Pegasus Investment Limited 联合公布，于2024年3月19 日，要约人就根据公司法第86条以协议安排方式将公司私有化，要求董事会向计划股份持有人提呈建 议，其中涉及注销计划股份，作为代价，就每股计划股份以现金向计划股东支付注销价，并撤销股份于 联交所的上市地位。 每股计划股份现金18.8港元较不受干扰日期(2024年3月15日)在联交所所报收市价每股14.04港元溢价约 33.90%，较最后交易日(2024年3月18日)在联交所所报收市价每股16.04港元溢价约17.21%。 最后交易日的交易量为974.15万股。不受干扰期间的平均每日交易量为 203.47万股。公司股价在最后交 易日上涨14.25%。相比之下，恒生指数在最后交易日上涨0.10%。 计划生效后，所有计划股份将予注销，且计划股份的任何股份证书于其后将不再具有所有权文件或证据 的效力。公司将于计划生效后立即根据上市规则第6.15(2)条向联交所申请撤销股份于联交所的上市地 位。 自公司首次公开发售以来，多项因素导致资本市场及公司股价受压，包括地缘局势紧张、供应 ...